Webinar

Targeting Domains of Schizophrenia with Individualized Therapy

Launch Date
11/07/2023
Credit Amount
0.5
Credit Expires
11/07/2024
This activity is part of a series

Faculty

Joshua Kantrowitz, MD
Associate Professor of Clinical Psychiatry
Columbia University Irving Medical Center
Director, Columbia Schizophrenia Research Center
Research Psychiatrist, New York State Psychiatric Institute
New York, NY
Nathan Kline Institute for Psychiatric Research
Orangeburg, NY
Joshua Kantrowitz, MD

Joshua Kantrowitz, MD, is an Associate Professor of Clinical Psychiatry at the Columbia University Department of Psychiatry and New York State Psychiatric Institute in New York, New York. He is also the Director of the Columbia Schizophrenia Research Center.

Dr. Kantrowitz’s career has focused on understanding the causes, prevention and treatment of psychotic disorders, especially schizophrenia, with a particular focus on N-methyl-D-aspartate (NMDA) receptor (NMDAR) and other early stage treatments and auditory cognition.  His research has demonstrated that NMDAR dysfunction may contribute to underlying neuroplasticity deficits. Dr. Kantrowitz has also conducted numerous early stage, target engagement biomarker studies with novel therapeutics using neurophysiological and neuroimaging biomarkers.

Dr. Kantrowitz has published over 80 peer-reviewed scientific papers in these fields.

Explore By Section
Statement of Need Learning Objective Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

Late-stage investigational treatments for schizophrenia have been able to target not only the positive symptoms of schizophrenia, but also the negative and cognitive symptoms as well. This could allow health care professionals (HCPs) the ability to individualize treatment plans to meet the specific needs of their patients in the near future. HCPs, however, may be unaware of the effects of these novel therapies and the varying domains of schizophrenia that the treatments can influence.

In the third installment of this three-part Journal Club series, Targeting Domains of Schizophrenia with Individualized Therapy, expert faculty will present the latest information on targeted treatments for schizophrenia phenotypes to help HCPs make the best choices in individualized therapies for their patients.

Learning Objective

Assess current and emerging data for therapies for the treatment of varying schizophrenia phenotypes

Financial Support

Supported in whole or in part by an educational grant from Sunovion and Otsuka.

Target Audience

Psychiatrists, nurse practitioners (NPs), physician associates (PAs), psychiatric nurses, and pharmacists

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 0.5

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) Credit for learning and change.

Physicians (ACCME) 0.5

CME Outfitters, LLC, designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.5

This activity is designated for 0.5 contact hours.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Pharmacists (ACPE) 0.5

This application-based activity is approved for 0.5 contact hours (0.05 CEUs) of continuing pharmacy credit.
Activity UAN: JA0007185-0000-23-095-H01-P

PAs (AAPA) 0.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 0.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABPN MOC

ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. Kantrowitz reports the following financial relationships:

Advisory Board: Jazz Pharmaceuticals, Inc.; Karuna Therapeutics; Leal Therapeutics; MedinCell; and Merck & Co., Inc.

Consultant: AlphaSights; Antheum; Clarivate; Clearview; ECRI Institute; Evoke Pharma; ExpertConnect; Evoke Pharma; First Thought; GKA; GlobalData; Guidepoint Global, LLC.; Health Monitor; Jefferies; Market Plus; MEDACorp, Inc.; Otsuka America Pharmaceutical, Inc.; Putnam; Reckner; Slingshot Biosciences, Inc.; SmartAnalyst; SR One Capital Management; Techspert.io Ltd; Third Bridge; Trinity; VoxNeuro Inc.; and Wedbush

Grants and Research Support: Supported by the NIMH, Boehringer Ingelheim; Cerevance; Click Therapeutics, Inc., Corcept; Neurocrine Biosciences, Inc.; Roche; Sunovion Pharmaceuticals Inc.; and Pharmaceutical Holdings Co., Ltd.

Stock Shareholder (directly purchased): GSK

Disclosures were obtained from the following peer reviewer and CME Outfitters, LLC, staff, with no disclosures to report:

  • Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer)
  • Mary Gleason, PhD (planning committee)
  • Kellie Busby, PharmD, BCPP (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

JC-027-110723-90

Targeting Domains of Schizophrenia with Individualized Therapy
Event Date: 11/07/2023
Register

Activities in the Series

Neuropsychiatric
11/07/2023

Targeting Domains of Schizophrenia with Individualized Therapy

0.5
Register Learn More
Neuropsychiatric
10/23/2023

TAAR1: More Than Just Another Receptor in Schizophrenia

0.5
Register Learn More